The 2021 CSCO breast cancer guidelines (7) also recommended adjuvant chemotherapy combined with targeted therapy; thus, adjuvant chemotherapy and targeted therapy have become the standard postoperative therapeutic regimens for HER2-positive breast cancer, including triple-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.